Multiple gut-liver axis abnormalities in children with obesity with and without hepatic involvement
S Guercio Nuzio1, M Di Stasi1, L Pierri1
1Pediatrics, Department of Medicine and Surgery, University of Salerno, Baronissi, Italy.
Insights
Gut-liver axis dysfunction, including increased intestinal permeability, is linked to pediatric obesity and liver issues. Targeting this axis may help prevent and treat these conditions.
Area of Science:
- Pediatric Gastroenterology
- Hepatology
- Metabolic Disorders
Background:
- Gut-liver axis (GLA) dysfunction is implicated in obesity and related liver complications.
- Understanding GLA components in pediatric obesity with liver disease is crucial.
Purpose of the Study:
- To concurrently explore multiple GLA components in a pediatric obese population.
- To investigate GLA dysfunction in children with and without obesity-related liver disease.
Main Methods:
- Study included 32 children: 9 controls and 23 with obesity (OB+).
- Assessed small intestinal bacterial overgrowth (SIBO), intestinal permeability (LMR), endotoxin, ethanol, and calprotectin.
- Utilized auxologic, ultrasonographic, and laboratory parameters.
Main Results:
- Increased intestinal permeability (pathological LMR) was observed in 11/23 obese children, correlating with liver disease severity.
- Elevated LMR correlated with higher ethanolaemia and endotoxaemia.
- Increased permeability was a risk factor for developing steatosis; SIBO was present only in obese children.
Conclusions:
- GLA dysfunction, evidenced by increased permeability, ethanol, and endotoxin, is present in pediatric obesity with hepatic complications.
- Modulating the GLA may offer a therapeutic target for preventing and treating these conditions.
Background:
Gut-liver axis (GLA) dysfunction appears to play a role in obesity and obesity-related hepatic complications.
Objectives:
This study sought to concurrently explore several GLA components in a paediatric obese population with/without liver disease.
Methods:
Thirty-two children (mean age 11.2 years) were enrolled: nine controls with normal weight and 23 patients with obesity (OB+). Of the 23 patients OB(+), 12 had not steatosis (ST-), and 11 had steatosis (ST+) (associated [n = 8] or not [n = 3] with hypertransaminasaemia [ALT +/-]). Subjects were characterized by using auxologic, ultrasonographic and laboratory parameters. A glucose hydrogen breath test was performed to test for small intestinal bacterial overgrowth, a urinary lactulose/mannitol ratio (LMR) was obtained to assess intestinal permeability, and tests for transaminases, blood endogenous ethanol, endotoxin and faecal calprotectin were also conducted.
Results:
Eleven out of 23 patients OB(+) (p < 0.05) exhibited pathological (>90th percentile of the control group values) LMR, with values paralleling the grade of liver involvement (normal weight < OB[+] < OB[+]ST[+]ALT[-] < OB[+)]ST[+]ALT[+] [p < 0.05]). LMR significantly correlated with ethanolaemia (r = 0.38, p = 0.05) and endotoxaemia (r = 0.48, p = 0.015) concentrations. Increased permeability was a risk factor for the development of steatosis (p < 0.002). SIBO was present only in patients with obesity. Faecal calprotectin concentrations were within normal limits in all subjects.
Conclusions:
Increased permeability, endogenous ethanol and systemic endotoxin concentrations reflect some GLA dysfunction in obesity and its hepatic complications. Pending further results to establish their potential causative roles, the modulation of the GLA appears to represent a possible target for the prevention and treatment of these conditions.
Related Concept Videos
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Gut-Brain Axis
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...


